Dosing to rash: A phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503)
2014 ◽
Vol 50
(2)
◽
pp. 302-308
◽
J.R. Brahmer
◽
J.W. Lee
◽
A.M. Traynor
◽
M.M. Hidalgo
◽
J.M. Kolesar
◽
...
2006 ◽
Vol 1
(7)
◽
pp. 673-678
◽
Gregory A. Masters
◽
Sigui Li
◽
Afshin Dowlati
◽
Stefan Madajewicz
◽
Corey Langer
◽
...
2006 ◽
Vol 1
(7)
◽
pp. 673-678
Gregory A. Masters
◽
Sigui Li
◽
Afshin Dowlati
◽
Stefan Madajewicz
◽
Corey Langer
◽
...
1995 ◽
Vol 12
(1-2)
◽
pp. 155
1993 ◽
Vol 10
(1-2)
◽
pp. 85-89
Nicholas A. Pavlidis
◽
George Klouvas
◽
Costas Nicolaides
◽
Apostolos Karantanas
◽
Marios Beer
◽
...
2009 ◽
Vol 28
(1)
◽
pp. 91-97
◽
Anne M. Traynor
◽
Ju-Whei Lee
◽
Gerald K. Bayer
◽
John M. Tate
◽
Sachdev P. Thomas
◽
...
1992 ◽
Vol 8
(2)
◽
pp. 139
1989 ◽
Vol 17
(3)
◽
pp. 197-201
◽
David S. Ettinger
◽
Dianne M. Finkelstein
◽
Ross C. Donehower
◽
Alex Y. C. Chang
◽
Michael Green
◽
...
1990 ◽
Vol 6
(1-2)
◽
pp. 58-59
2004 ◽
Vol 22
(14_suppl)
◽
pp. 7037-7037
◽
G. A. Masters
◽
R. Xu
◽
C. Langer
◽
A. Dowlati
◽
S. Madajewicz
◽
...
1997 ◽
Vol 41
(1)
◽
pp. 75-78
◽
D. R. Gandara
◽
Martin J. Edelman
◽
John J. Crowley
◽
Derick H. M. Lau
◽
Robert B. Livingston
Close
Export Citation Format
Close
Share Document
Close